The science of megestrol acetate delivery: Potential to improve outcomes in cachexia

BioDrugs

Volumn 19, Issue 3, 2005, Pages 179-187

  Femia, Robert A ^a   Goyette, Richert E ^b  

^a Par Pharmaceutical   (United States)

^b Hematology/Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MEGESTROL ACETATE; PROGESTERONE; PYRROLE DERIVATIVE; WATER;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADDISON DISEASE; AREA UNDER THE CURVE; CACHEXIA; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG SAFETY; DRUG SOLUBILITY; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; GLUCOSE INTOLERANCE; HORMONE ACTION; HORMONE RELEASE; HUMAN; METABOLIC REGULATION; NONHUMAN; OSTEOPOROSIS; PHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SUSPENSION; TABLET; THROMBOEMBOLISM; TREATMENT OUTCOME; VERTEBRA FRACTURE;

ADMINISTRATION, ORAL; CACHEXIA; CYTOKINES; DRUG DELIVERY SYSTEMS; HUMANS; MEGESTROL ACETATE; NANOTECHNOLOGY; SUSPENSIONS; TABLETS; TREATMENT OUTCOME;

EID: 22244467103     PISSN: 11738804     EISSN: None     Source Type: Journal    
DOI: 10.2165/00063030-200519030-00004     Document Type: Review

References (51)

1. Schacter L, Rozencweig M, Canetta R, et al. Megestrol acetate: clinical experience. Cancer Treat Rev 1989; 16 (1): 49-63
2. Tisdale MJ. Biology of cachexia. J Natl Cancer Inst 1997; 89 (23): 1763-73
3. Strasser F, Bruera ED. Update on anorexia and cachexia. Hematol Oncol Clin North Am 2002; 16 (3): 589-617
4. Akner G, Cederholm T. Treatment of protein-energy malnutrition in chronic nonmalignant disorders. Am J Clin Nutr 2001; 74 (1): 6-24
5. Milani RV, Mehra MR, Endres S, et al. The clinical relevance of circulating tumor necrosis factor-alpha in acute decompensated chronic heart failure without cachexia. Chest 1996; 110 (4): 992-5
6. Ferrari R. The importance of cachexia in the syndrome of heart failure. Eur Heart J 1997; 18 (2): 187-9
7. Roubenoff R, Roubenoff RA, Cannon JG, et al. Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation. J Clin Invest 1994; 93 (6): 2379-86
8. Lewis MI. Apoptosis as a potential mechanism of muscle cachexia in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166 (4): 434-6
9. Rigaud D, Angel LA, Cerf M, et al. Mechanisms of decreased food intake during weight loss in adult Crohn's disease patients without obvious malabsorption. Am J Clin Nutr 1994; 60 (5): 775-81
10. Mitch WE. Robert H Herman Memorial Award in Clinical Nutrition Lecture, 1997: mechanisms causing loss of lean body mass in kidney disease. Am J Clin Nutr 1998; 67 (3): 359-66
11. Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 1999; 59 (18): 4493-501
12. Inui A. Cancer anorexia-cachexia syndrome: current issues in research and management. CA Cancer J Clin 2002; 52 (2): 72-91
13. Farinha A, Bica A, Tavares P. Improved bioavailability of a micronized megestrol acetate tablet formulation in humans. Drug Dev Ind Pharm 2000; 26 (5): 567-70
14. Loose-Mitchell DS, Stancel GM. Estrogens and progestins. In: Hardman JG, Limbird LE, Gilman AG, editors. Goodman and Gilman's the pharmacological basis of therapeutics. 10th ed. New York: McGraw-Hill, 2001: 1597-634
15. Par Pharmaceutical. Megestrol acetate oral suspension. Spring Valley (NY): Par Pharmaceutical, Inc., 2004 [online]. Available from URL: http:// www.parpharm.com/downloads/megestroloral_po.pdf [Accessed 2005 Apr 5]
16. Pascual Lopez A, Figuls M, Urrutia Cuchi G, et al. Systematic review of megestrol acetate in the treatment of anorexia-cachexia syndrome. J Pain Symptom Manage 2004; 27 (4): 360-9
17. Tomiska M, Tomiskova M, Salajka F, et al. Palliative treatment of cancer anorexia with oral suspension of megestrol acetate. Neoplasma 2003; 50 (3): 227-33
18. Gagnon B, Bruera E. A review of the drug treatment of cachexia associated with cancer. Drugs 1998; 55 (5): 675-88
19. Mantovani G, Maccio A, Massa E, et al. Managing cancer-related anorexia/ cachexia. Drugs 2001; 61 (4): 499-514
20. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993; 11 (4): 762-7
21. Beutler B, Cerami A. The biology of cachectin/TNF: a primary mediator of the host response. Annu Rev Immunol 1989; 7: 625-55
22. Alvarez B, Quinn LS, Busquets S, et al. Direct effects of tumor necrosis factor alpha (TNF-alpha) on murine skeletal muscle cell lines: bimodal effects on protein metabolism. Eur Cytokine Netw 2001; 12 (3): 399-410
23. Langen RC, Schols AM, Kelders MC, et al. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-kappaB. FASEB J 2001; 15 (7): 1169-80
24. Jezek P. Possible physiological roles of mitochondrial uncoupling proteins: UCPn. Int J Biochem Cell Biol 2002; 34 (10): 1190-206
25. Busquets S, Sanchis D, Alvarez B, et al. In the rat, tumor necrosis factor alpha administration results in an increase in both UCP2 and UCP3 mRNAs in skeletal muscle: a possible mechanism for cytokine-induced thermogenesis? FEBS Lett 1998; 440 (3): 348-50
26. Berg M, Fraker DL, Alexander HR. Characterization of differentiation factor/ leukaemia inhibitory factor effect on lipoprotein lipase activity and mRNA in 3T3-L1 adipocytes. Cytokine 1994; 6 (4): 425-32
27. Zaki MH, Nemeth JA, Trikha M. CNTO 328, a monoclonal antibody to IL-6, inhibits human tumor-induced cachexia in nude mice. Int J Cancer 2004; 111 (4): 592-5
28. Francis J, MohanKumar PS, MohanKumar SM, et al. Systemic administration of lipopolysaccharide increases plasma leptin levels: blockade by soluble in-terleukin-1 receptor. Endocrine 1999; 10 (3): 291-5
29. Mantovani G, Maccio A, Bianchi A, et al. Megestrol acetate in neoplastic anorexia/cachexia: clinical evaluation and comparison with cytokine levels in patients with head and neck carcinoma treated with neoadjuvant chemotherapy. Int J Clin Lab Res 1995; 25 (3): 135-41
30. Mantovani G, Maccio A, Esu S, et al. Medroxyprogesterone acetate reduces the production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. Biochem Soc Trans 1997; 25 (2): 296S
31. Trikha M, Corringham R, Klein B, et al. Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 2003; 9 (13): 4653-65
32. Beck SA, Tisdale MJ. Effect of megestrol acetate on weight loss induced by tumour necrosis factor alpha and a cachexia-inducing tumour (MAC16) in NMRI mice. Br J Cancer 1990; 62 (3): 420-4
33. Ackermann M, Kirchner H, Atzpodien J. Low dose megestrol acetate can abrogate cachexia in advanced tumor patients receiving systemic interferon-alpha and/or interleukin-2 based antineoplastic therapy. Anticancer Drugs 1993; 4 (5): 585-7
34. Flier JS. Clinical review 94: what's in a name? In search of leptin's physiologic role. J Clin Endocrinol Metab 1998; 83 (5): 1407-13
35. Schwartz MW, Dallman MF, Woods SC. Hypothalamic response to starvation: implications for the study of wasting disorders. Am J Physiol 1995; 269 (5 pt 2): R949-57
36. Schwartz MW, Seeley RJ. Seminars in medicine of the Beth Israel Deaconess Medical Center: neuroendocrine responses to starvation and weight loss. N Engl J Med 1997; 336 (25): 1802-11
37. Morley JE, Silver AJ. Anorexia in the elderly. Neurobiol Aging 1988; 9 (1): 9-16
38. Martinez M, Hernanz A, Gomez-Cerezo J, et al. Alterations in plasma and cerebrospinal fluid levels of neuropeptides in idiopathic senile anorexia. Regul Pept 1993; 49 (2): 109-17
39. Karcic E, Philpot C, Morley JE. Treating malnutrition with megestrol acetate: literature review and review of our experience. J Nutr Health Aging 2002; 6 (3): 191-200
40. Morley JE. Orexigenic and anabolic agents. Clin Geriatr Med 2002; 18 (4): 853-66
41. Herkert O, Kuhl H, Sandow J, et al. Sex steroids used in hormonal treatment increase vascular procoagulant activity by inducing thrombin receptor (PAR-1) expression: role of the glucocorticoid receptor. Circulation 2001; 104 (23): 2826-31
42. Bladbjerg EM, Skouby SO, Andersen LF, et al. Effects of different progestin regimens in hormone replacement therapy on blood coagulation factor VII and tissue factor pathway inhibitor. Hum Reprod 2002; 17 (12): 3235-41
43. Kuhl H. Effects of progestogens on haemostasis. Maturitas 1996; 24 (1-2): 1-19
44. Loprinzi CL, Jensen MD, Jiang NS, et al. Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clin Proc 1992; 67 (12): 1160-2
45. Wermers RA, Hurley DL, Kearns AE. Osteoporosis associated with megestrol acetate. Mayo Clin Proc 2004; 79 (12): 1557-61
46. Nelson KA. The cancer anorexia-cachexia syndrome. Semin Oncol 2000; 27 (1): 64-8
47. Graham KK, Mikolich DJ, Fisher AE, et al. Pharmacologic evaluation of megestrol acetate oral suspension in cachectic AIDS patients. J Acquir Immune Defic Syndr 1994; 7 (6): 580-6
48. Aisner J, Parnes H, Tait N, et al. Appetite stimulation and weight gain with megestrol acetate. Semin Oncol 1990; 17 (6 Suppl. 9): 2-7
49. Aisner J, Tchekmedyian NS, Moody M, et al. High-dose megestrol acetate for the treatment of advanced breast cancer: dose and toxicities. Semin Hematol 1987; 24 (2 Suppl. 1): 48-55
50. Par Pharmaceutical, Inc. FDA accepts for filing Par Pharmaceutical's NDA for megestrol acetate oral suspension NCD. Press release 2004 Sep 16 [online]. Available from URL: http://www.parpharm.com/html/nf/PR_ 20040916.html [Accessed 2005 Apr 5]
51. Data on file, Par Pharmaceutical, Inc., 2004